Chemotherapy should be primarily reserved for patients with high proliferation tumours, except possibly for pancreatic primary sites Ki-67 of >10%, and widespread disease might support systemic chemotherapy as a first-line treatment (Öberg 2001). This evidence concerns the gene MKI67 and neoplasm.